Recently, Miner and colleagues have observed that the CSF concentration of sPDGFRβ is elevated in AD patients compared to controls, and it correlated with the levels of markers for AD progression, such as p-tau and T-tau in the CSF [30]. This evidence concerns the gene MAPT and Alzheimer disease.